Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Neoplasms 2Thoracic Neoplasms 1Squamous Non-small Cell Lung Cancer 1Squamous Non Small Cell Lung Cancer 1Solid Tumors 1Solid Tumor, Adult 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Non-small Cell Lung Cancer Metastatic 1Neoplasm Metastasis 1Lung Neoplasms 1Lung Diseases 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 98Gemcitabine 70Paclitaxel 59Docetaxel 52Carboplatin 49Cisplatin 40Nivolumab 39Capecitabine 35Pemetrexed 33Fluorouracil 32Bevacizumab 32Cetuximab 31130-nm albumin-bound paclitaxel 28Trastuzumab 26Irinotecan 24Albumin-Bound Paclitaxel 24Fulvestrant 22Leucovorin 20Oxaliplatin 18Panitumumab 17abemaciclib 16Ipilimumab 16Cyclophosphamide 15cemiplimab 14atezolizumab 14Letrozole 14palbociclib 12Lapatinib 12Drug Therapy 12Doxorubicin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasm Metastasis × necitumumab × Clear all
NCT02411591 2020-07-09

A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Eli Lilly and Company

Phase 1 Completed
66 enrolled 20 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡